Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
A typical presentation of moxifloxacin-induced DRESS syndrome with pulmonary involvement: a case report and review of the literature.
BMC Pulm Med
July 2022
Beijing Jishuitan Hospital, Fourth Clinical College of Peking University, No. 31 Xinjiekou East Street, Xicheng District, Beijing, 100035, China.
Background: Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome is a kind of hypersensitivity drug reaction involving the skin and multiple internal organ systems. Moxifloxacin has rarely been reported to be a drug that is associated with DRESS syndrome. Lungs are less frequently involved in DRESS syndrome, but their involvements may herald more serious clinical processes.
View Article and Find Full Text PDFSevere sequelae in bilateral acute iris transillumination syndrome secondary to the use of oral moxifloxacin: a case report.
J Med Case Rep
September 2021
NeURos research group, Escuela de Medicina y Ciencias de la salud, Universidad del Rosario, Carrera 24 # 63 C 69, Bogotá, Colombia.
Background: Moxifloxacin is a fourth-generation fluoroquinolone used as a second-line treatment for multiple bacterial infections. Uveitis has been described as an adverse effect related to this medication. Although several case reports have been published describing uveitis and bilateral acute iris transillumination syndrome related to moxifloxacin, we present a unique case of a patient with severe sequelae associated with bilateral acute iris transillumination syndrome secondary to the use of oral moxifloxacin.
View Article and Find Full Text PDFMoxifloxacin-Induced Thrombocytopenia Mediated by Moxifloxacin-Dependent IgM and IgG Antiplatelet Antibodies: A Case Report.
Cureus
September 2020
Departments of Medicine and Pediatrics, University of Maryland School of Medicine, Baltimore, USA.
Moxifloxacin is a rare but important cause of drug-induced immune thrombocytopenia (DIT). We describe a patient who presented with an acute onset of severe thrombocytopenia complicated by petechial rash, epistaxis, and melena. Recent new drug exposures included moxifloxacin and two proton pump inhibitors.
View Article and Find Full Text PDFMoxifloxacin-induced QT interval prolongation and torsades de pointes: a narrative review.
Expert Opin Drug Saf
October 2018
a Department of Pharmacy , University of Peshawar, Peshawar , Khyber Pakhtunkhwa , Pakistan.
Introduction: Moxifloxacin is widely used for the treatment of a number of infectious diseases because of its favorable pharmacological profile and high clinical success rate. However, it is often criticized for its higher risk of QTc interval prolongation (QTIP) and torsades de pointes (TdP).
Areas Covered: A review of published literature on moxifloxacin-related QTIP and TdP.
Moxifloxacin Increases Heart Rate in Humans.
Antibiotics (Basel)
February 2017
Tarizona eHealth Services, Tucson, AZ 85732, USA.
(1) : We assessed the effect of moxifloxacin on heart rate, and reviewed the heart rate effects of other antibiotics; (2) : A total of 335 normal volunteers had 12-lead electrocardiograms recorded at multiple time points before and during treatment with moxifloxacin and with placebo in seven consecutive, thorough QT studies of crossover design; (3) : The average baseline heart rate across the seven studies was 61.5 bpm. The heart rate after moxifloxacin dosing was analyzed at five time points shared by all seven studies (hours 1, 2, 3, 12 and 24).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!